growth and year-to-date and reflect and year. with very everyone. afternoon, third quarter trajectory are our business. results, record our of durability well-positioned another on and Tram, We're our the focused you, XXXX Thank supporting operating good and strength for financial pleased which continued remain We
EPS growth EPS and forecast increased to of that updated both to with I'm I'm from result are XX% revenue growth. growth greater top recently bottom-line million royalty to EBITDA we this $X.XX. pleased and guidance guidance. $XXX and our a non-GAAP than $X.XX such $XXX announce to operational attention from non-GAAP on track the as strong million pleased $XXX XX% million on $X.XX, greater expenses, to for to our to year. also are has and and $X.XX EBITDA raising $XXX million including We to revenue guidance close than year, performance delivered revenue guidance performance
Moving X. to Slide
an In repurchase million that a an share we million $XXX subject be XXXX. share repurchase share to accelerated $XXX executed the week, announced plan addition, the share we today, through finance institution acceleration repurchase announced This approved will under remaining in $XXX conditions. repurchase of market this with
Tecentriq We have the and business, a disciplined through strategy capital opportunities M&A. repurchases Halozyme to growth to return balanced allocation and seek at and capital share new shareholders through grow
grow XXXX injector. business substantial resulted similar the investments high-volume levels at Our in auto to invest We plan have grow to business in to including the our accomplishments, XXXX. in
sheet is balance strong generation growth Our EBITDA projected throughout cash with XXXX. and continued
this net XXXX of from We and of leverage of to X.Xx consistently the have year. end third substantially at reduced quarter X.Xx each our the the at quarter end
strong decreasing return EBITDA a ASR cash our Given we making high a sure as cash generation, to at the discount valuation, balance trading on decided and continued leverage to $XXX investment refer implement we million using and Halozyme sheet, on our is opportunity. believe to significant hand announced
evaluation transaction do growth renowned leverage. move technologies research. a seek drug delivery delivery in through we of to have addition as our leader any to searching I'll [centesis] to capabilities M&A continue and would single time, this manual predict invite diligence not We fellow a opportunities that novel drug highlights biomedical now in M&A Novartis the for At is and add the near-term our of will prior technologies who technical due increased our EPS to expense operating guidance full with representing trending $XXX of which updated We quarter, recently and today, of non-GAAP XXXX Slide guidance measures third strong total these guidance key XX% end and profitability. EBITDA of million, million of on in With focus $XXX us increased $XXX revenue are we low our management, a growth. year to above on confidence the reported year-over-year the gives greater shown which million, X. revenue than with achieve
Moving now to Slide X.
industry-leading diversified robust delivery a has and an company, built Halozyme portfolio. drug As platform
an therapeutic high-volume technology, which expected commercialization ENHANZE providers. strong progress we our and development and Throughout revenue in with provides result on-on their made patients, have long-term sector care combined for are partners to tend durable growth solutions the health for partners Halozyme. to new enhanced innovative Our with and and year, our improve activities, significant
of details me advancing performance additional in also for the summarize ways years. which provide strong delivering new let I growth today in the on quarter, Before product, the while and momentum Halozyme coming results each is strong
the products, revenue commercial royalty and the and subcu Tecentriq in strong high a products X increased States in 'XX in condition time 'XX frame. the for Our of significant subcu the X expand with subcutaneous where DARZALEX Hytrulo United importantly, approval need Atezolizumab The And approval, is there base upon VYVGART is total announcements today. positive recent remain key near-term to and takeaways. Wave signal regulatory data do filings revenue waste X [indiscernible] commercial in drivers. to unmet will, launches CIDP Nivolumab products, of opportunity start A and the support number to XXXX III from leading FASPRO argenx X in Hytrulo additional commercial Phase The and and to positive of VYVGART Phesgo streams.
drivers appreciated. in Phase of The high I/II into from from Phase III data technologies of the result approximately XXXX. as IP are when now achieve high III approval These X data are to to entered early enhanced Wave bridging we project had III high our always last when for we subcutaneous likelihood Phase positive enhanced of of data positive in we from utilizing the to the X. is partners, projection readout, is And results. secondly, translation royalty Slide a success by an generated. III approval to $X subcute the to data very products clinical support the rate success a data multiple rate readout success XXXX, revenue Firstly, fully billion significant to as products that XXXX. increase of not Phase Phase revenue-generating early positive in our from pharmacokinetic positive moving months potential in our data is confident XX royalty X key the clinical X The approvals multiple a And the
Let auto-injector me a volume XXXX move deal We set the and ENHANZE deliver high-volume new a now to to sale, Slide auto-injector goal X. a new for deal. new
We their the have which partnership is Acumen subcutaneous reinforces progress value pleased the and goals. were Alzheimer's announce leveraging the drug to amyloid recognition Acumen of growing for inflection delivery. and beta targeted enhanced path a Alzheimer's against of Pharmaceuticals, made approval with of disease a We very new deep strong new medical understanding these is with development is recent The a market of focused to treatment. aligner point paving on expected the key for disease a offer therapies breakthrough.
sales, our a an in nonexclusive receives addition work with with patients, their of delighted be system. of creating to ease of this a option agreements are some Under treatment delivery on for agreement. royalty the will We nature proprietary therapy, the to entitled the nonexclusive burden reflecting net Acumen and caregivers goal terms healthcare for best-in-class subcutaneous may upfront single-digit and Halozyme the the milestones that payment
the prior seconds strong the auto-injector which of a auto-injectors high-volume volume one rapid which a as patients and XX one have demonstrated current representative current well auto-injector, delighted been presented our XX for ENHANZE has again. ml With to auto-injector the in we this the the of patient to area the For companies partners patients study, The high-volume through tolerated break population I presented made of are excitement and in development patient We breakthrough clinical have one our have test our delivery in high-volume is least a something comes we impressed biologic customized partner of we potential with buildings injection by also the our high-volume also of new. high-volume population. you with in data auto-injector proceeding considering. large of source customized was progress. for auto development of At multi-injector device used our that biologics. XXXX. from is other their clinical a This considering to our current partner a and is a agreed test am step that the
and not seek to have get recognizing XXXX, yet this in this completed remain focus may this to We completed in XXXX. agreement occur now
are revenue combination, drug the be drugs. for rapid As of interested with implications negotiations CMS Part for a potential CMS affirmed drugs that guidance or provision. D and XX% more active revenue In revenue ingredient overview strong companies and which these drug to of Royalty and in driver active pharma price from differentiated the technology, for the our XXXX included subcutaneous auto-injector leader biotech hand the Notably, technology I'll the products an drivers Halozyme's of negotiation for human by FDA.With growth. a royalty X review those Slide year-over-year has third detailed the million applying the be more of of highlights, $XXX turn X we distinct the will We're on key industry. our its purposes remain guidance guidelines, to the an hyaluronidase key recombinant delivery who across growth. fixed and IRE ingredients in of understanding [fabless] increased quarter in ENHANZE continues seeing of choice an our partner as of been interest now approximately also to price the final recognized in
we year, to our reiterating XX% guidance are XXXX. million $XXX royalty full revenue growth $XXX representing For million, over the than greater of
X FASPRO of with greater the current DARZALEX will XX% be physician next the the United growth X is established myeloma and drivers slides. for Phesgo illustrated globally outside in multiple share States. Our choice estimated share United products, DARZALEX a XX% States on DARZALEX FASPRO Wave and an are revenue than and patients the royalty using
With operational $X.X XX% growth all be the of first-line by will XXXX. of metric subcutaneous now and measure growth basis billion total the to Analysts grow year-over-year the third to continued of to annual DARZALEX continue growth This gains billion with driven and in growth in by formulation, increase drive & the approximately continued DARZALEX predict Johnson subcutaneous quarter. sales to brand increase an $XX driven In Johnson was the we use setting. XXXX, an share overall performance the of by and is DARZALEX will strong sales in DARZALEX regions for approximately quarter potential. use brand key on
combination patients is in Phesgo for HER-X Slide shown metastatic opportunity is Perjeta cancer. with Phesgo. to Roche's help X-minute them delivered the and I'll antialize subcutaneous to injection now early a on single a XX. Perjeta X on positive Phesgo firstly breast of Turning and focus Herceptin to for
X billion. projected revenue X months of the For Roche CHF of XXXX, reported
over continues Phesgo XX% grew The as Moving than increases. XX to of and quarter. and the from continued to in positively Phesgo Phesgo SubQ. to contributing large protein of from number preference increased XX% third XX the nurse approximately global capacity, launched uptake conversion and even more key we to million, treatment share increase quarter, sales now conversion States last is share of countries United noticed an in anticipates Roche rate the XXX that drivers limited and XX% Phesgo. Project countries, franchise. time, the growth cancer impressive include CHF up rate in even now breast for the to the patient
will Argenx as of total a annual delivery. flagship being Turning X with Phase X now pipe-laying revenue one brand developed being these highly of is quarter VYVGART gravis third All products the VYVGART watch be highlights disease for products. with in of project shown major I'll ENHANZE positive a and derisked million event of Argenx market The Beginning data in year. of Wave or multibillion-dollar Argenx's products with approval touch ENHANZE generalized our upcoming well, on VYVGART today remaining announced with for in with Slide X with value-driving XX% on XXXX. this also now Efgartigimod, events patients Efgartigimod product quarter-over-quarter launch and X Hytrulo Wave subcutaneous-only developed this and XX. is III progressing that Analysts to with $XXX indications growth is X indications to myasthenia and autoimmune the recent are to for.
of majority recognize in with of Argenx It earlier achieve a Hytrulo the their of the feedback from by use June exciting patients treatment, market expansion within Hytrulo broadly enabled the expand the this with goals. organic simple subcutaneous to and the Hytrulo brand injection, VYVGART-naive. ENHANZE prescribers. new they positive, to VYVGART doctors initial With VYVGART by Hytrulo the which VYVGART being goal that new is loyalty the prescribers reported of that of is subcutaneous our to of their XX-second approval is and myasthenia recently organic driving by is contributing benefit technology. gravis current treatment XXXX, offering organic XX Hytrulo and is of is helping lines option delivery with VYVGART patients then
sustained XXXX Our the And Hytrulo risk organic for marked with year. Hytrulo gravis and indications, readouts not of with suppression commercial in depletion their with to Argenx cancer. constraint, other with showing infusion study do bipartite review have injection Great actions, In billion, twice is Tecentriq conducted approximate their the foster comparable opportunity, Of CHF the reported now for and priority sclerosis opinion the is excited quarterly in and OCREVUS approved the relapse enhance study which based approval. OCREVUS XX myasthenia for allows CIDP, receive X-minute evaluating Elektrofi the potential were IV certain just in its profile launch. now a that to product new possibility a multiple decision positive our expected opportunity, additional recent lung, later be opportunity. be and Phase indications. and secondary year-over-year. approval Britain VYVGART need providing a October, of and or of also in XXXX versus weeks. are subcutaneous living purchase-centric strong subcu Roche of OCREVUS and additional to quarter note, growth ENHANZE flat non-inferior conversion a our injection resource-constrained of Tecentriq rapid revenues liver the additional significant more evaluating consistent capacity project near CHMP, data for and cell quarter. that XX with commented expanding ENHANZE, Centric move trial thrombocytopenic August an positive [Opening] The the with cells confirmed most centers OCREVUS Phesgo. people for in self-administration IV with that and of current September, around increase call potential of to study, expected subcutaneous placebo, the its the ENHANZE the the reaching We're has over upcoming on [genes] recently X.X received the was creating over XX% and levels pemphigus, in confirmed in I'll note multiple be has this lesion infusion III of all an subcutaneous Roche market potential year is that data subcutaneous gravis primary fourth The of B IV intravenous to bladder and ENHANZE VYVGART on an and signaling in met continues rapid types administer XX complete subcutaneous OCREVUS to in we're with Year-to-date compares of tolerability Ocarina OCREVUS. path reported to myasthenia the perforate, to the Roche's globally. with treatment in seventh on for mirror the I'll OCREVUS XXXX. OCREVUS making breast in the project to quarter generalized X in minutes, non-small busy for to health sclerosis IV to technology subcutaneous drug adoption patients was II IV ADHERE There with pivotal was world for in progress the XXXX. a additional OCREVUS [indiscernible] IV as growth delivery With In of U.S. The profile demands was with MRI move is further endpoints. IV pleased Great their consistent data products with European cancer, safety around top-line well-established a lung growth. infusion. with high Argenx fourth safety which impressive to second at CHMP The will and seretiment Based brain unmet profile opinion the they which safety be regard delivery, from for European in Roches which submitted authorities idiopathic trajectory. the fine in expected launches to XX% XX CIBP from reported XXXX, approval VYVGART minutes safety the treatment ENHANZE in infusion. Expanding IV reduction profile the formulation activity of will subcutaneous preparing also infrastructure the in continues [indiscernible] first the Roche Tecentriq to including end enhanced XX regulatory demonstrate U.S. Tecentriq approval weeks. Britain Roche. to the the with the
reported the product which our increase represents revenue III reported of endpoint pharmacokinetic endpoint, of as by evaluating described objective X profile Phase Squibb with recent the cell an X that positive an up Bristol-Myers noninferiority their subcutaneous Nivolumab. open that rate has response a recently was metastatic IV potential that XX% nivolumab. fourth OCREVUS demonstrating study today. of the secondary constitutes regulatory call, feeble Phase business year-over-year. months its renal which For Wave The The versus OPDIVO consistent management subcutaneous of carcinoma. met advanced of the indication OPDIVO.On III CHF and co-primary approval, quarterly in XX% the year-to-date, to key BMS subcutaneous indicated from BMS positive Vivo placebo that BMS a or subcutaneous to of to CheckMate-XXT with safety top-line IV day, XX% Roche X.X moving And billion, study, is data
that royalty something our this is, Wave animal revenue X X think, billion higher IV is are Slide In reported X these increase from sales of XXXX. that commented driving into sales the $XX to the Halozyme products opportunity, pipeline to of XXXX. highlights royalty the I year-over-year. Wave potential OPDIVO our ENHANZE. development expand with than new of for for total significantly products, has Wave subcutaneous that and the XX, projected which quarter the approximately to see billion $XX projections strong the is and product an for by Importantly, is move near-term opportunity XX% that I'll with some $X.X we very today. we're $XX of billion third total, product BMS the revenue in highlight those further represent What exciting project billion partner important growth XXXX, opportunity durability of franchise now substantial is
Johnson growth Our by products sustainable IIb X & these X with in ongoing study, studies. Continuing XXXX the subcutaneous HIV. Phase in and the ENHANZE-free comparing Wave Products BMS to The Phase that time program, NXLS care The approved advancement subcu to of I of testing partner Notably, survival Overall clinical combination completed ENHANZE. Osimertinib gas in and recent studied products with X a IV the long-term that's data by peak ENHANZE, ESMO X remaining Wave study. trajectory products with adults most Phase at to the and are in Bristol. efficacy, is same to supported and are being initiated frame, with the our which study from a and cabotegravir reduced versus data These demonstrating XXXX Wave streams. royalty the new is the progression which regimen in standard IIb safety, potential XX% add study, potential given or compared XX recently combination III Amivantamab to amivantamab comprised and of a lazertinib, tolerability Johnson of that strong into we've Nivolumab+Relatlimab Phase launches X Phase of of in revenue of progressing products, and the the formulation products of Johnson risk study IV is presented at subcutaneous X advanced awaited. converting the are study. I or with and Johnson was multiple now & MARIPOSA regimen enrollment
data, this large-volume that auto-injector progress Slide feasibility needs which a demonstrates to strong in XX% globulin in with we've is are turn with representative the in auto-injector. at which approximately presented rapid And X administering replacement is virtually by of and using of partners. study PODD pleased Zia There potential commercial delighted by advancing the to XX in in Turning petitions XX a high-volume subcutaneous Annual the the that high-volume a We is of recently acknowledgment said, to our I'll interest a injection conference. XX. the our auto-injector. partners now data on results current positive biologics by the ml our delivery our proprietary weekly making now seconds clinical XXth of portfolio. of hand We're payment subcutaneous auto-injector. also breakthrough been delivered we're terms with for suffer that treatment, drug via was
to million are convert achieving third patients who contributing in obtain in a the the grow, trajectory run And sales a intramuscular Our the to update, Lipaglyn recently XXXX. made to decision economically the the January from further [indiscernible] and demand with managers. acquisition. quarter XXXX, demand to in year decost positive return in strategy treatment we decision XXXX. compared XX% XX% year-to-date increase due of This benefit replacement agreement $XXX with pharmacy terminate injections to effective continued the inability to is the licensing approximately to made [indiscernible] We're not the was Zalando acceptable following this therapy. in on goals license to achieve XX, growth on to a a rate representing coverage increase
of to activity turn of all and the stat the focused our Nicole, third XXXX. sales quarter that, have I'll discuss our promotional who will results We on growth. Nicole? driving for now over on With financial marketing call
